You just read:

Helsinn Group and Chugai Pharma Marketing Enter Into Agreement for Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination (NEPA) in the UK and Ireland and for Palonosetron Monotherapy in the UK

News provided by

Helsinn Group

17 Jul, 2014, 07:00 BST